VYNE Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

Rhea-AI Summary

VYNE Therapeutics Inc. (Nasdaq: VYNE) announced on February 28, 2023, that it has regained compliance with Nasdaq's minimum bid price requirement. The company received a Notification Letter indicating that its common stock's closing bid price was at $1.00 per share or greater for the last 10 consecutive business days, from February 13 to February 27, 2023. VYNE is focused on developing innovative therapies for immuno-inflammatory conditions, utilizing its proprietary bromodomain & extra-terminal (BET) domain platform, which includes lead programs VYN201 and VYN202.

Positive

• Regained compliance with Nasdaq minimum bid price requirement, indicating improved stock performance.
• Closing bid price maintained at $1.00 per share or greater for 10 consecutive business days.

Negative

• None.

BRIDGEWATER, N.J., Feb. 28, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that it received a notification letter (the "Notification Letter on Compliance") from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") on February 28, 2023, indicating that the Company has regained compliance with the minimum bid price requirement set forth in Rule 5550(a)(2) of the Nasdaq Listing Rules.

According to the Notification Letter on Compliance, the staff of Nasdaq has determined that for the last 10 consecutive business days, from February 13, 2023 through February 27, 2023, the closing bid price of the Company's common stock had been at $1.00 per share or greater, and the Company has regained compliance with Rule 5550(a)(2) of the Nasdaq Listing Rules.

About VYNE Therapeutics Inc.
VYNE’s mission is to improve the lives of patients by developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. The Company’s unique and proprietary bromodomain & extra-terminal (“BET”) domain platform includes lead programs VYN201 (pan-BET inhibitor) and VYN202 (selective-BET inhibitor), and access to a library of small molecule BET inhibitors for the potential treatment of immuno-inflammatory conditions licensed from Tay Therapeutics Limited.

For more information about VYNE Therapeutics Inc. or its product candidates, visit www.vynetherapeutics.com. VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE’s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts.

Investor Relations:
John Fraunces
LifeSci Advisors, LLC
917-355-2395
jfraunces@lifesciadvisors.com

Tyler Zeronda
VYNE Therapeutics Inc.
908-458-9106
Tyler.Zeronda@vynetx.com

FAQ

What did VYNE Therapeutics announce on February 28, 2023?

VYNE Therapeutics announced that it regained compliance with Nasdaq's minimum bid price requirement.

What is the significance of the Notification Letter received by VYNE?

The Notification Letter indicates that VYNE's common stock has met the required closing bid price of $1.00 per share for 10 consecutive business days.

What are the lead programs developed by VYNE Therapeutics?

VYNE's lead programs include VYN201, a pan-BET inhibitor, and VYN202, a selective-BET inhibitor.

How does VYNE Therapeutics plan to treat immuno-inflammatory conditions?

VYNE utilizes its proprietary bromodomain & extra-terminal (BET) domain platform for developing therapies.